NCT01921335
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patients must have one measurable lesion that can be accurately measured in at least one dimension and is greater than 10 mm
Exclusions: Patients with leptomeningeal disease as the only site of CNS involvement
https://ClinicalTrials.gov/show/NCT01921335